These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7393125)

  • 1. Salicylate in Pepto-Bismol.
    Med Lett Drugs Ther; 1980 Jul; 22(15):63. PubMed ID: 7393125
    [No Abstract]   [Full Text] [Related]  

  • 2. The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate).
    Nwokolo CU; Mistry P; Pounder RE
    Aliment Pharmacol Ther; 1990 Apr; 4(2):163-9. PubMed ID: 2104082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bismuth subsalicylate: history, chemistry, and safety.
    Bierer DW
    Rev Infect Dis; 1990; 12 Suppl 1():S3-8. PubMed ID: 2406853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salicylate toxicity associated with administration of Percy medicine in an infant.
    Lewis TV; Badillo R; Schaeffer S; Hagemann TM; McGoodwin L
    Pharmacotherapy; 2006 Mar; 26(3):403-9. PubMed ID: 16503721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salicylate toxicity from chronic bismuth subsalicylate use.
    Halani S; Wu PE
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption of salicylate and bismuth from a bismuth subsalicylate--containing compound (Pepto-Bismol).
    Pickering LK; Feldman S; Ericsson CD; Cleary TG
    J Pediatr; 1981 Oct; 99(4):654-6. PubMed ID: 7277115
    [No Abstract]   [Full Text] [Related]  

  • 7. Pepto-bismol and salicylate levels.
    Shanbrom E
    Mayo Clin Proc; 1989 Jan; 64(1):129. PubMed ID: 2911212
    [No Abstract]   [Full Text] [Related]  

  • 8. Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol).
    Jungreis AC; Schaumburg HH
    Neurology; 1993 Jun; 43(6):1265. PubMed ID: 8192812
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pediatric practice. Special risks of various drugs. II. Asprin and salicylates, bismuth subnitrate].
    LABRAM C
    Concours Med; 1962 Mar; 84():1933-4. PubMed ID: 14461324
    [No Abstract]   [Full Text] [Related]  

  • 10. Salicylate absorption from a bismuth subsalicylate preparation.
    Feldman S; Chen SL; Pickering LK; Cleary TG; Ericsson CD; Hulse M
    Clin Pharmacol Ther; 1981 Jun; 29(6):788-92. PubMed ID: 7226711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro effect of 2 pharmaceutical preparations containing bismuth on the fermentative capacity of intestinal bacteria].
    León-Barúa R; Tello-Casanova R
    Acta Gastroenterol Latinoam; 1985; 15(3):157-64. PubMed ID: 3836544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue necrosis from injection of bismuth subsalicylate in vegetable oil.
    LEWIS GM
    Arch Derm Syphilol; 1946 Dec; 54(6):732. PubMed ID: 20277319
    [No Abstract]   [Full Text] [Related]  

  • 13. Pepto-Bismol mimicking pancreatic calcification.
    Bernstein D; Barkin JS
    Am J Gastroenterol; 1992 Nov; 87(11):1677-9. PubMed ID: 1442703
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of subsalicylate bismuth on absorption of doxycycline.
    Ericsson CD; Feldman S; Pickering LK; Cleary TG
    JAMA; 1982 Apr; 247(16):2266-7. PubMed ID: 7040708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photo quiz. Pepto Bismol poisoning.
    Hearney EG; Fuhrer J; Marioz P
    Clin Infect Dis; 1996 Jul; 23(1):37,159. PubMed ID: 8816125
    [No Abstract]   [Full Text] [Related]  

  • 16. Warning against products containing bismuth subsalicylate.
    Henderson IW
    Can Med Assoc J; 1980 Nov; 123(9):848. PubMed ID: 7437988
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of bismuth subsalicylate on ciprofloxacin bioavailability.
    Rambout L; Sahai J; Gallicano K; Oliveras L; Garber G
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2187-90. PubMed ID: 7811043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
    Mahony DE; Woods A; Eelman MD; Burford N; Veldhuyzen van Zanten SJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):431-3. PubMed ID: 15616328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness.
    Liang D; Ma J; Wei B
    Sci Rep; 2021 Jan; 11(1):2605. PubMed ID: 33510326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaphylaxis to Pepto-Bismol.
    More D; Whisman B; Johns J; Hagan L
    Allergy; 2002 Jun; 57(6):558. PubMed ID: 12028127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.